Vivanza Biosciences Ltd Financials
Company Logo

Vivanza Biosciences Ltd Financial Statement

Vivanza Biosciences Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue1.59
Operating Expense1.48
Net Profit0.01
Net Profit Margin0.63
Earning Per ShareTBA
EBIDTA0.10
Effective Tax RateTBA
Invest in Vivanza Biosciences Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Vivanza Biosciences Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual14.41
Operating Expenses Annual13.61
Operating Profit Annual0.85
Interest Annual0.41
Depreciation0.01
Net Profit Annual0.32
Tax Annual0.11

Vivanza Biosciences Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.10
Cash Flow from Operations1.78
Cash Flow from Investing-0.04
Cash Flow from Financing-1.76
Cash Flow at the End0.09

Vivanza Biosciences Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)5.97
PBIT Margin (%)5.90
PBT Margin (%)-8.12
Net PROFIT Margin (%)2.22
Return On Networth / Equity (%)7.02
Return On Networth /Employed (%)8.98
Return On Assets (%)3.38
Total Debt / Equity (X)1.08
Asset Turnover Ratio (%)1.52

Vivanza Biosciences Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual0.03
Total Current Assets Annual14.33
Non Current Assets Annual2.54
Total Shareholders Funds Annual4.72
Total Assets Annual16.87

Vivanza Biosciences Ltd Earning Calls

EPS (INR)

Expected

0.01

Reported

0.00

Surprise

-100.00%

Jun 2024

EPS beaten by -100.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 23, 2024, Vivanza Biosciences Ltd has a market capitalization of 27.16 Cr. Value Research classifies it as a Micro-Cap company.
No, Vivanza Biosciences Ltd is not debt-free with a debt-to-equity ratio of 0.69.
In FY 2023 , Vivanza Biosciences Ltd recorded a total revenue of approximately 14.41 Cr marking a significant milestone in the company's financial performance.
Vivanza Biosciences Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.5% and 0.2% annually, respectively..
Vivanza Biosciences Ltd's current PE ratio is 84.88.
Vivanza Biosciences Ltd's ROCE averaged 10.4% from the FY ending March 2022 to 2024, with a median of 10.5%. It peaked at 10.6% in March 2024, reflecting strong capital efficiency over the period..
Vivanza Biosciences Ltd's latest EBIT is Rs. 0.84 Cr, surpassing the average EBIT of Rs. 0.94 Cr over the 5 years..